Synthesis and characterization of NS-2028 analogues by Pyriochou, Anastasia et al.
BioMed  Central
Page 1 of 2
(page number not for citation purposes)
BMC Pharmacology
Open Access Poster presentation
Synthesis and characterization of NS-2028 analogues
Anastasia Pyriochou*1, Athanasios Giannis2 and Andreas Papapetropoulos1
Address: 1Lab for Molecular Pharmacology, Dept of Pharmacy, University of Patras, Greece and 2Institute for Organic Chemistry, University of 
Leipzig, Leipzig, Germany
Email: Anastasia Pyriochou* - apyriohou@upatras.gr
* Corresponding author    
Background
Soluble guanylyl cyclase (sGC) is a ubiquitously expressed
enzyme that synthesizes the second messenger cGMP.
sGC has low basal activity which can be stimulated several
hundred-fold by nitric oxide. Although, many NO activa-
tors and stimulators have been described only two chem-
ically related sGC inhibitors exist: ODQ and NS-2028.
The use of the above mentioned sGC inhibitors has
helped researchers unravel many of the actions of the NO/
sGC/cGMP pathway. The mechanism of action of NS-
2028 and ODQ is believed to involve oxidation of the
heme iron, making sGC unresponsive to NO. The aim of
the present work was to sythesize and characterize a
number of NS-2028 analogues for their ability to inhibit
sGC. To this end 5 such analogues were generated and are
shown below in Figure 1.
Results
Compounds C was as effective and potent as NS-2028,
suggesting that substituting the Br atom in position 8 with
a bulkier m-trifluoromethylphenyl group does not alter
the activity of NS-2028. Compound B that carries a p-
methoxyphenyl group in position 8 was as effective
NS2028 and ODQ, but was less potent, as it only inhib-
ited SNP-induced cGMP formation by 43% at 0.1 Ì, com-
pared to >80% observed with ODQ or NS-2028 when
used at the same concentration. Compound A that has an
expanded oxadiazolo ring was both less potent and less
effective in blocking SNP-induced cGMP production.
Expanding the oxazin ring to a benzodiazepinone ring
resulted in a compound (compound D) with markedly
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reduced inhibitory activity. Finally, compound E in which
the oxadiazolo ring has been converted to a triazolo ring
was devoid of any sGC inhibitory activity.
Conclusion
We conclude that the oxadiazolo ring of NS-2028/ODQ is
of major importance for the action of this class of inhibi-
tors.